Atomo Diagnostics
Atomo Diagnostics Awarded A$2.4M Grant for Syphilis Test Development
The firm said it will develop a test for use at home and at the point of care to aid the diagnosis of syphilis and distinguish between active and past infections.
Atomo, NG Biotech Partner on Blood-Based Pregnancy Test
The tests will incorporate NG Biotech's CE-marked human chorionic gonadotropin assay into Atomo Diagnostics' Pascal blood testing instrument.
Atomo Diagnostics, Viatris Ink Deal With Unitaid to Expand HIV Self-Test Access
The deal is expected to reduce the cost per test of HIV self-tests by 50 percent in low- and middle-income countries.
Atomo Diagnostics, Access Bio Ink Deal to Commercialize Two Rapid COVID-19 Antibody Tests
According to the agreement, Access Bio must sell at least 2 million tests by Sept. 30, 2021, to keep its exclusive rights in North America.
Atomo, NG Biotech Ink Deal for Coronavirus Testing Devices
Atomo also said it has closed an oversubscribed initial public offering and that it intends to float its shares on the Australian Securities Exchange mid-month.
May 30, 2018
Dec 7, 2017
WHO Panel Approves Atomo's HIV Self-Test
Oct 10, 2017